Prostamax
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Synthetic tetrapeptide (Lys-Glu-Asp-Pro) bioregulator proposed to support prostate function and provide anti-proliferative effects via tissue-specific gene expression regulation.
Methodological Note: >95% of published research on this peptide originates from the Khavinson bioregulation group (Institute of Bioregulation and Gerontology, St. Petersburg). Independent replication by Western laboratories is lacking. All evidence should be interpreted with this single-group limitation in mind.
Quick Facts
| Property | Value |
|---|---|
| Also Known As | KEDP tetrapeptide, Lys-Glu-Asp-Pro |
| Category | Reproductive / Khavinson Bioregulator |
| Sequence | Lys-Glu-Asp-Pro (KEDP, 4 amino acids) |
| Molecular Weight | ~474 Da |
| Molecular Formula | C19H32N4O9 |
| PubChem CID | N/A — research peptide |
| Administration | SubQ |
| Typical Dose Range | 10-20 mcg/day (from Khavinson protocols) |
| Half-Life | Very short (minutes; typical of tetrapeptides) |
| Storage | Lyophilized: -20C long-term; 2-8C short-term. Reconstituted: 2-8C for 2-4 weeks |
| FDA Status | NOT FDA-approved. Approved in Russia as bioregulator; no Western regulatory approval |
| WADA Status | Prohibited under S0 (non-approved substances) |
Mechanism of Action
Prostamax (Lys-Glu-Asp-Pro) is a synthetic tetrapeptide developed by the Khavinson group, derived from the amino acid analysis of prostatic tissue extracts. It is related to Prostatilen, an earlier natural prostate extract preparation used in Russian clinical practice.
The proposed mechanism involves chromatin remodeling in prostate-associated cell types. In vitro studies demonstrated that Prostamax induced changes in heterochromatin structure of human lymphocytes, causing partial decondensation consistent with the Khavinson epigenetic bioregulation model (PMID: 15612551). However, this study was performed in lymphocytes, not prostatic cells, limiting the tissue-specificity conclusions.
Prostamax is proposed to regulate gene expression in prostatic tissue, supporting normal prostate function and providing anti-proliferative effects relevant to benign prostatic hyperplasia (BPH). It also modulates fibroblast differentiation signaling in prostate tissue during cellular aging (PMID: 20586252).
The precise molecular targets, receptor interactions, and signaling pathways remain uncharacterized by standard pharmacological methods.
Key Research Areas
- Chromatin remodeling — Heterochromatin decondensation in lymphocytes (not prostate cells)
- Prostate tissue regulation — Proposed anti-proliferative and differentiation support
- Fibroblast differentiation — Modulation of signaling factors in aging prostate fibroblasts
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | 0 | No randomized controlled trials |
| Human observational | 0 | No human clinical studies |
| Animal in vivo | 0 | No dedicated animal studies |
| In vitro | 2 | Chromatin in lymphocytes; THP-1 cell study |
| Systematic reviews | 1 | Khavinson self-review (2021) |
Clinical Applications
- Sexual Health — Proposed prostate function support (no clinical evidence)
Protocols Using This Peptide
- No established clinical protocols. Used in Khavinson bioregulation research protocols only.
Ageless Peps Products
- APWS-Prostamax-Vial — Prostamax Vial, wholesale only
Dosing Reference
Research Dosing Ranges (from literature)
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| SubQ | 10-20 mcg | Daily | 10-20 days | Khavinson protocols |
Cycling
Khavinson protocols typically recommend 10-20 day treatment courses with 1-3 month intervals. No independent validation exists.
Contraindications & Safety
- Contraindications: Unknown — no systematic safety studies. Should NOT be used as a substitute for standard prostate cancer screening or BPH treatment
- Common side effects: Unknown — no human clinical data
- Drug interactions: Unknown — no interaction studies
- Pregnancy/nursing: Not applicable (male prostate bioregulator)
- Special populations: No data available
Synergistic Combinations
Per Khavinson protocols (unvalidated):
- Testagen + Prostamax — Combined male reproductive support
- Vilon + Prostamax — Immune + prostate support
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| 15612551 | Prostamax Effect on Heterochromatin of Human Lymphocytes | 2004 | In vitro |
| 34834147 | Peptide Regulation of Gene Expression: A Systematic Review | 2021 | Systematic Review |
| 35408963 | Peptides Regulating Proliferative Activity in THP-1 Cell Line | 2022 | In vitro |
References
- PMID 15612551 — Heterochromatin study in lymphocytes
- PMID 20586252 — Fibroblast differentiation in prostate aging
- PMID 34834147 — Systematic review of peptide gene regulation
Related
#peptide #reproductive #khavinson-bioregulator #subq